Use of anatabine to treat inflammation and methods of synthesizing anatabine

Use of anatabine to treat inflammation and methods of synthesizing anatabine

H:\xd\Interwoven\NRPortbl\DCC\SXD\I33562121.docx-8/03/2017 Pharmaceutical compositions comprising an isolated form of anatabine or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low level inflammation. In another aspect, methods for the synthet...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Raju, Muppala Sarveswara, Puthiaparampil, Tom Thomas, Williams, Jonnie R, David, Thomas Kanathkunn
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Raju, Muppala Sarveswara
Puthiaparampil, Tom Thomas
Williams, Jonnie R
David, Thomas Kanathkunn
description H:\xd\Interwoven\NRPortbl\DCC\SXD\I33562121.docx-8/03/2017 Pharmaceutical compositions comprising an isolated form of anatabine or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low level inflammation. In another aspect, methods for the synthetic preparation of anatabine involve reacting benzophenoneimine with 3-aminomethyl pyridine to form benzylhydrylidene pyridin-3-yl-methyl-amine. The benzylhydrylidene-pyridin-3-yl-methyl-amine is treated with a non-nucleophilic base and a dielectrophile, such as cis- 1,4-dichloro-2-butene, followed by acidification, then basification, to provide anatabine. 100 ______ E_ RACEMIO MIXTURE )S (S-(-)-ANATABINE Lu co40 0 10 100 200 400 600 800 1000 DOSE (pg/mL)
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2017201593A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2017201593A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2017201593A13</originalsourceid><addsrcrecordid>eNrjZPAJLU5VyE9TSMxLLElMysxLVSjJVygpSk0sUcjMS8tJzM1NLMnMzwPKpyjkppZk5KcUg5QXV-aVZKQWZ1Zl5qUj9PIwsKYl5hSn8kJpbgZlN9cQZw_d1IL8-NTigsTk1LzUknjHUCMDQ3MgNrU0djQ0Jk4VAGmiNrQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Use of anatabine to treat inflammation and methods of synthesizing anatabine</title><source>esp@cenet</source><creator>Raju, Muppala Sarveswara ; Puthiaparampil, Tom Thomas ; Williams, Jonnie R ; David, Thomas Kanathkunn</creator><creatorcontrib>Raju, Muppala Sarveswara ; Puthiaparampil, Tom Thomas ; Williams, Jonnie R ; David, Thomas Kanathkunn</creatorcontrib><description>H:\xd\Interwoven\NRPortbl\DCC\SXD\I33562121.docx-8/03/2017 Pharmaceutical compositions comprising an isolated form of anatabine or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low level inflammation. In another aspect, methods for the synthetic preparation of anatabine involve reacting benzophenoneimine with 3-aminomethyl pyridine to form benzylhydrylidene pyridin-3-yl-methyl-amine. The benzylhydrylidene-pyridin-3-yl-methyl-amine is treated with a non-nucleophilic base and a dielectrophile, such as cis- 1,4-dichloro-2-butene, followed by acidification, then basification, to provide anatabine. 100 ______ E_ RACEMIO MIXTURE )S (S-(-)-ANATABINE Lu co40 0 10 100 200 400 600 800 1000 DOSE (pg/mL)</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2017</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20170330&amp;DB=EPODOC&amp;CC=AU&amp;NR=2017201593A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20170330&amp;DB=EPODOC&amp;CC=AU&amp;NR=2017201593A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Raju, Muppala Sarveswara</creatorcontrib><creatorcontrib>Puthiaparampil, Tom Thomas</creatorcontrib><creatorcontrib>Williams, Jonnie R</creatorcontrib><creatorcontrib>David, Thomas Kanathkunn</creatorcontrib><title>Use of anatabine to treat inflammation and methods of synthesizing anatabine</title><description>H:\xd\Interwoven\NRPortbl\DCC\SXD\I33562121.docx-8/03/2017 Pharmaceutical compositions comprising an isolated form of anatabine or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low level inflammation. In another aspect, methods for the synthetic preparation of anatabine involve reacting benzophenoneimine with 3-aminomethyl pyridine to form benzylhydrylidene pyridin-3-yl-methyl-amine. The benzylhydrylidene-pyridin-3-yl-methyl-amine is treated with a non-nucleophilic base and a dielectrophile, such as cis- 1,4-dichloro-2-butene, followed by acidification, then basification, to provide anatabine. 100 ______ E_ RACEMIO MIXTURE )S (S-(-)-ANATABINE Lu co40 0 10 100 200 400 600 800 1000 DOSE (pg/mL)</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2017</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZPAJLU5VyE9TSMxLLElMysxLVSjJVygpSk0sUcjMS8tJzM1NLMnMzwPKpyjkppZk5KcUg5QXV-aVZKQWZ1Zl5qUj9PIwsKYl5hSn8kJpbgZlN9cQZw_d1IL8-NTigsTk1LzUknjHUCMDQ3MgNrU0djQ0Jk4VAGmiNrQ</recordid><startdate>20170330</startdate><enddate>20170330</enddate><creator>Raju, Muppala Sarveswara</creator><creator>Puthiaparampil, Tom Thomas</creator><creator>Williams, Jonnie R</creator><creator>David, Thomas Kanathkunn</creator><scope>EVB</scope></search><sort><creationdate>20170330</creationdate><title>Use of anatabine to treat inflammation and methods of synthesizing anatabine</title><author>Raju, Muppala Sarveswara ; Puthiaparampil, Tom Thomas ; Williams, Jonnie R ; David, Thomas Kanathkunn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2017201593A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2017</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>Raju, Muppala Sarveswara</creatorcontrib><creatorcontrib>Puthiaparampil, Tom Thomas</creatorcontrib><creatorcontrib>Williams, Jonnie R</creatorcontrib><creatorcontrib>David, Thomas Kanathkunn</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Raju, Muppala Sarveswara</au><au>Puthiaparampil, Tom Thomas</au><au>Williams, Jonnie R</au><au>David, Thomas Kanathkunn</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Use of anatabine to treat inflammation and methods of synthesizing anatabine</title><date>2017-03-30</date><risdate>2017</risdate><abstract>H:\xd\Interwoven\NRPortbl\DCC\SXD\I33562121.docx-8/03/2017 Pharmaceutical compositions comprising an isolated form of anatabine or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low level inflammation. In another aspect, methods for the synthetic preparation of anatabine involve reacting benzophenoneimine with 3-aminomethyl pyridine to form benzylhydrylidene pyridin-3-yl-methyl-amine. The benzylhydrylidene-pyridin-3-yl-methyl-amine is treated with a non-nucleophilic base and a dielectrophile, such as cis- 1,4-dichloro-2-butene, followed by acidification, then basification, to provide anatabine. 100 ______ E_ RACEMIO MIXTURE )S (S-(-)-ANATABINE Lu co40 0 10 100 200 400 600 800 1000 DOSE (pg/mL)</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_AU2017201593A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title Use of anatabine to treat inflammation and methods of synthesizing anatabine
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T10%3A36%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Raju,%20Muppala%20Sarveswara&rft.date=2017-03-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2017201593A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true